The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) after intensive induction chemotherapy and are not able to complete intensive curative therapy.
SEPTEMBER 4, 2020